English

Omega Therapeutics, Inc.

EDGAR

OMGA Current report (8-K) · filed 2024-12-31

18 filing records in this dataset, filed from 2021-07-09 to 2024-12-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

2.61 million USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 2612000 USD Source

Operating margin

-628.64%

2024 Q3 · %

Exact inputs and evidence

Operating Income: -16420000 USD Source
Revenue: 2612000 USD Source

Operating cash flow

-14 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -38500000 USD Source
Operating Cash Flow: -24500000 USD Source

Free cash flow

-14 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -38500000 USD Source
Operating Cash Flow: -24500000 USD Source
Capital Expenditure: 947000 USD Source
Capital Expenditure: 931000 USD Source

Cash and cash equivalents: 30.4 million USD 2024-09-30 Source
Exact value

30400000 USD
Long-term debt including current maturities: 15.6 million USD 2024-09-30 Source
Exact value

15587000 USD
Shares outstanding: 55.2 million shares 2024-09-30 Source
Exact value

55159219 shares

Reported share-count change

0.03% · 17.4 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

55141838 shares · 2023-09-30· Source
55159219 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

8.1 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Revenue: 3094000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 2105000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 2360000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 2134000 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 2612000 USD · 2024-07-01 – 2024-09-30 Source

Net income

-73.1 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Net income: -97428000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -77214000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -20129000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -16305000 USD · 2024-04-01 – 2024-06-30 Source
Net income: -16444000 USD · 2024-07-01 – 2024-09-30 Source

Operating cash flow

-55.6 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -91500000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -74420000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -11800000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -24500000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -11800000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -38500000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -24500000 USD · 2024-01-01 – 2024-06-30 Source

Capital expenditure

2.06 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Capital expenditure: 2869000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 1758000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 535000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 931000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 535000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 947000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 931000 USD · 2024-01-01 – 2024-06-30 Source

Free cash flow

-57.6 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -91500000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -74420000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -11800000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -24500000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -11800000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -38500000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -24500000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 2869000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 1758000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 535000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 931000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 535000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 947000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 931000 USD · 2024-01-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-12-31.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2023-12-31
Operating income: 4 of 11 periods available· newest 2023-12-31
Net income: 4 of 11 periods available· newest 2023-12-31
Operating cash flow: 4 of 11 periods available· newest 2023-12-31
Capital expenditure: 4 of 11 periods available· newest 2023-12-31
Total assets: 3 of 11 periods available· newest 2023-12-31
Total liabilities: 3 of 11 periods available· newest 2023-12-31
Current assets: 3 of 11 periods available· newest 2023-12-31
Current liabilities: 3 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2023-12-31
Shares outstanding: 3 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+49.3%

Prior period

USD 2.07 million

2022-01-01 – 2022-12-31
Current period

USD 3.09 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

3094000 − 2073000 = 1021000 USD

2073000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
3094000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Year-over-year change in Revenue: 1021000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 3094000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#1951953 Filing: 000095017024038094 Input fundies:Revenue: 2073000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#1953206 Filing: 000095017024038094
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 5.27 million

Prior period

−USD 102.7 million

2022-01-01 – 2022-12-31
Current period

−USD 97.43 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-97428000 − -102701000 = 5273000 USD

-102701000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-97428000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Year-over-year change in Net income: 5273000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -97428000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2900995 Filing: 000095017024038094 Input fundies:NetIncome: -102701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2902490 Filing: 000095017024038094
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 7.02 million

Prior period

−USD 98.52 million

2022-01-01 – 2022-12-31
Current period

−USD 91.5 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-91500000 − -98515000 = 7015000 USD

-98515000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-91500000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Year-over-year change in Operating cash flow: 7015000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -91500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2255259 Filing: 000095017024038094 Input fundies:OperatingCashFlow: -98515000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2169515 Filing: 000095017024038094
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+107.9%

Prior period

USD 1.38 million

2022-01-01 – 2022-12-31
Current period

USD 2.87 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

2869000 − 1380000 = 1489000 USD

1380000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
2869000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Year-over-year change in Capital expenditure: 1489000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2869000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2173333 Filing: 000095017024038094 Input fundies:CapitalExpenditure: 1380000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2174753 Filing: 000095017024038094
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 3.09 million 100% of revenue
Operating costs Derived USD 103.36 million 3,340% of revenue
Operating income −USD 100.26 million −3,240% of revenue
Tax, interest and other Derived −USD 2.83 million −92% of revenue
Net income −USD 97.43 million −3,149% of revenue

Cash

Operating cash flow −USD 91.5 million −2,957% of revenue
Capital expenditure USD 2.87 million 93% of revenue
Free cash flow Derived −USD 94.37 million −3,050% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 45,956% of revenue.
2022 Operating loss: operating costs were 5,057% of revenue.
2023 Operating loss: operating costs were 3,340% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	144000	66176000 Derived	-66032000	2248000 Derived	-68280000	-59076000 Derived	Source 2021-01-01 – 2021-12-31: 144000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -66032000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -68280000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -57609000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1467000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2073000	104839000 Derived	-102766000	-65000 Derived	-102701000	-99895000 Derived	Source 2022-01-01 – 2022-12-31: 2073000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -102766000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -102701000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -98515000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1380000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	3094000	103355000 Derived	-100261000	-2833000 Derived	-97428000	-94369000 Derived	Source 2023-01-01 – 2023-12-31: 3094000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -100261000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -97428000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -91500000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 2869000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.1M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	144000	Revenue: 144000 Open source
20222022-12-31	Revenue	2073000	Revenue: 2073000 Open source
20232023-12-31	Revenue	3094000	Revenue: 3094000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

49.3% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 144000 Open source
20222022-12-31	Year over year	1,339.6%	Revenue: 2073000 Open source Revenue: 144000 Open source
20232023-12-31	Year over year	49.3%	Revenue: 3094000 Open source Revenue: 2073000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,240.5% 2023

Net margin -3,148.9% 2023

Free cash flow margin -3,050.1% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-45,855.6%	Operating Income: -66032000 Open source Revenue: 144000 Open source
20222022-12-31	Operating margin	-4,957.4%	Operating Income: -102766000 Open source Revenue: 2073000 Open source
20232023-12-31	Operating margin	-3,240.5%	Operating Income: -100261000 Open source Revenue: 3094000 Open source
20212021-12-31	Net margin	-47,416.7%	Net Income: -68280000 Open source Revenue: 144000 Open source
20222022-12-31	Net margin	-4,954.2%	Net Income: -102701000 Open source Revenue: 2073000 Open source
20232023-12-31	Net margin	-3,148.9%	Net Income: -97428000 Open source Revenue: 3094000 Open source
20212021-12-31	Free cash flow margin	-41,025%	Revenue: 144000 Open source Operating Cash Flow: -57609000 Open source Capital Expenditure: 1467000 Open source
20222022-12-31	Free cash flow margin	-4,818.9%	Revenue: 2073000 Open source Operating Cash Flow: -98515000 Open source Capital Expenditure: 1380000 Open source
20232023-12-31	Free cash flow margin	-3,050.1%	Revenue: 3094000 Open source Operating Cash Flow: -91500000 Open source Capital Expenditure: 2869000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -91.5M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-57609000	Operating Cash Flow: -57609000 Open source
20222022-12-31	Operating cash flow	-98515000	Operating Cash Flow: -98515000 Open source
20232023-12-31	Operating cash flow	-91500000	Operating Cash Flow: -91500000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -94.4M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-59076000	Operating Cash Flow: -57609000 Open source Capital Expenditure: 1467000 Open source
20222022-12-31	Free cash flow	-99895000	Operating Cash Flow: -98515000 Open source Capital Expenditure: 1380000 Open source
20232023-12-31	Free cash flow	-94369000	Operating Cash Flow: -91500000 Open source Capital Expenditure: 2869000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

71.6% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	14%	Total Liabilities: 32705000 Open source Total Assets: 233333000 Open source
20222022-12-31	Liabilities / assets	27.4%	Total Liabilities: 40027000 Open source Total Assets: 145998000 Open source
20232023-12-31	Liabilities / assets	71.6%	Total Liabilities: 146350000 Open source Total Assets: 204366000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.35× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	19.13×	Current Assets: 229286000 Open source Current Liabilities: 11983000 Open source
20222022-12-31	Current assets / current liabilities	6.26×	Current Assets: 137590000 Open source Current Liabilities: 21964000 Open source
20232023-12-31	Current assets / current liabilities	3.35×	Current Assets: 89884000 Open source Current Liabilities: 26806000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 29.45 million Exact value Exact value: -29447000 USD 2020-01-01 – 2020-12-31: -29447000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Omega Therapeutics, Inc. · 2020-12-31 Omega Therapeutics, Inc. (edgar:1850838) Net Income: -29447000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29447000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017022003350/omga-20211231.htm#3613824 Filing: 000095017022003350 The citation records this snapshot. The page link may show a newer release later.	−USD 26.13 million Exact value Exact value: -26133000 USD 2020-01-01 – 2020-12-31: -26133000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Omega Therapeutics, Inc. · 2020-12-31 Omega Therapeutics, Inc. (edgar:1850838) Operating Cash Flow: -26133000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26133000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017022003350/omga-20211231.htm#2680547 Filing: 000095017022003350 The citation records this snapshot. The page link may show a newer release later.	USD 1.81 million Exact value Exact value: 1808000 USD 2020-01-01 – 2020-12-31: 1808000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Omega Therapeutics, Inc. · 2020-12-31 Omega Therapeutics, Inc. (edgar:1850838) Capital Expenditure: 1808000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1808000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017022003350/omga-20211231.htm#2687447 Filing: 000095017022003350 The citation records this snapshot. The page link may show a newer release later.	−USD 27.94 million Calculation and evidence -26133000 − 1808000 USD Exact free cash flow: -27941000 USD 2020-01-01 – 2020-12-31: -26133000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1808000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Omega Therapeutics, Inc. · 2020-12-31 Omega Therapeutics, Inc. (edgar:1850838) Free cash flow: -27941000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26133000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017022003350/omga-20211231.htm#2680547 Filing: 000095017022003350 Input fundies:CapitalExpenditure: 1808000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017022003350/omga-20211231.htm#2687447 Filing: 000095017022003350 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 68.28 million Exact value Exact value: -68280000 USD 2021-01-01 – 2021-12-31: -68280000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Omega Therapeutics, Inc. · 2021-12-31 Omega Therapeutics, Inc. (edgar:1850838) Net Income: -68280000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68280000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017023005328/omga-20221231.htm#3929902 Filing: 000095017023005328 The citation records this snapshot. The page link may show a newer release later.	−USD 57.61 million Exact value Exact value: -57609000 USD 2021-01-01 – 2021-12-31: -57609000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Omega Therapeutics, Inc. · 2021-12-31 Omega Therapeutics, Inc. (edgar:1850838) Operating Cash Flow: -57609000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57609000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017023005328/omga-20221231.htm#2928311 Filing: 000095017023005328 The citation records this snapshot. The page link may show a newer release later.	USD 1.47 million Exact value Exact value: 1467000 USD 2021-01-01 – 2021-12-31: 1467000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Omega Therapeutics, Inc. · 2021-12-31 Omega Therapeutics, Inc. (edgar:1850838) Capital Expenditure: 1467000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1467000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017023005328/omga-20221231.htm#2936149 Filing: 000095017023005328 The citation records this snapshot. The page link may show a newer release later.	−USD 59.08 million Calculation and evidence -57609000 − 1467000 USD Exact free cash flow: -59076000 USD 2021-01-01 – 2021-12-31: -57609000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1467000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Omega Therapeutics, Inc. · 2021-12-31 Omega Therapeutics, Inc. (edgar:1850838) Free cash flow: -59076000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57609000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017023005328/omga-20221231.htm#2928311 Filing: 000095017023005328 Input fundies:CapitalExpenditure: 1467000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017023005328/omga-20221231.htm#2936149 Filing: 000095017023005328 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 102.7 million Exact value Exact value: -102701000 USD 2022-01-01 – 2022-12-31: -102701000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Omega Therapeutics, Inc. · 2022-12-31 Omega Therapeutics, Inc. (edgar:1850838) Net Income: -102701000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -102701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2902490 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	−USD 98.52 million Exact value Exact value: -98515000 USD 2022-01-01 – 2022-12-31: -98515000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Omega Therapeutics, Inc. · 2022-12-31 Omega Therapeutics, Inc. (edgar:1850838) Operating Cash Flow: -98515000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -98515000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2169515 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	USD 1.38 million Exact value Exact value: 1380000 USD 2022-01-01 – 2022-12-31: 1380000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Omega Therapeutics, Inc. · 2022-12-31 Omega Therapeutics, Inc. (edgar:1850838) Capital Expenditure: 1380000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1380000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2174753 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	−USD 99.9 million Calculation and evidence -98515000 − 1380000 USD Exact free cash flow: -99895000 USD 2022-01-01 – 2022-12-31: -98515000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1380000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Omega Therapeutics, Inc. · 2022-12-31 Omega Therapeutics, Inc. (edgar:1850838) Free cash flow: -99895000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -98515000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2169515 Filing: 000095017024038094 Input fundies:CapitalExpenditure: 1380000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2174753 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 97.43 million Exact value Exact value: -97428000 USD 2023-01-01 – 2023-12-31: -97428000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Net Income: -97428000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97428000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2900995 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	−USD 91.5 million Exact value Exact value: -91500000 USD 2023-01-01 – 2023-12-31: -91500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Operating Cash Flow: -91500000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -91500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2255259 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	USD 2.87 million Exact value Exact value: 2869000 USD 2023-01-01 – 2023-12-31: 2869000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Capital Expenditure: 2869000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2869000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2173333 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.	−USD 94.37 million Calculation and evidence -91500000 − 2869000 USD Exact free cash flow: -94369000 USD 2023-01-01 – 2023-12-31: -91500000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 2869000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Omega Therapeutics, Inc. · 2023-12-31 Omega Therapeutics, Inc. (edgar:1850838) Free cash flow: -94369000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:56:36Z Snapshot: 9cec1098555344dc42e81485ec12b807c1be0d2792715c6ce6723718bd7bb36e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1850838?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -91500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2255259 Filing: 000095017024038094 Input fundies:CapitalExpenditure: 2869000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1850838/000095017024038094/omga-20231231.htm#2173333 Filing: 000095017024038094 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 1,106 latest values · 1,106 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001850838, 1850838, OMGA, edgar:1850838

Also known as Omega Therapeutics, Inc.

Omega Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation